12th May, 2017

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Clarification / Information on news item

With reference to your e-mail dated 12-May-17, referring to the news item appeared in Bloombergquint.com dated May 12, 2017, titled: "***https://www.bloombergquint.com/markets/2017/05/12/torrent-pharma-gets-four-us-fda observations-for-indrad-plan*** ", we hereby submit our response as follows:

USFDA inspectors have carried out audit of our Indrad Plant. Four observations have received from them relating to improvement in procedures and in documentation practices. None of the observations is concerning product quality or data reliability.

We have discussed the action plan during the audit process and a detailed response would be submitted within the stipulated time to FDA. We do not anticipate any business impact from this.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY